Emerging drugs for squamous cell lung cancer

Haiying Cheng, Marina Shcherba, Karthikeya Kandavelou, Yuanxin Liang, Huijie Liu, Roman Perez-Soler

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: The management of advanced NSCLC has been shifted by histology-driven treatment and molecularly targeted therapy, especially in lung adenocarcinoma. However, as the second most common histology in NSCLC, the treatment options for squamous cell lung cancer (SQCLC) remain very limited.

Areas covered: The review first discusses the role of histology in management of NSCLC and new cytotoxic agents in SQCLC, and then addresses genomic characterization and potential molecular targets in SQCLC. The article then provides an overview for several major categories of novel molecularly targeted therapies and immune-based strategies with particular attention to ongoing SQCLC trials.

Expert opinion: The key challenges in drug development are to uncover novel actionable targets and to identify predictive biomarkers. Progress in genomic analysis has identified some promising targetable genes and oncogenic pathways in SQCLC with a wave of targeted agents being tested in clinical trials. Immunotherapy has also raised great interest in management of SQCLC, especially agents targeting immune check points, cytotoxic T-lymphocyte antigen-4, programmed death-1 receptor and its ligands. Better understanding of tumor biology and development of novel targeted therapies will help to facilitate more effective personalized therapy for patients with this devastating illness.

Original languageEnglish (US)
Pages (from-to)149-160
Number of pages12
JournalExpert Opinion on Emerging Drugs
Volume20
Issue number1
DOIs
StatePublished - Mar 1 2015

Fingerprint

Squamous Cell Neoplasms
Lung Neoplasms
Pharmaceutical Preparations
Histology
Therapeutics
CTLA-4 Antigen
Death Domain Receptors
Cytotoxins
Expert Testimony
Immunotherapy
Biomarkers
Clinical Trials
Ligands
Genes
Neoplasms

Keywords

  • Biomarker
  • New treatment
  • NSCLC
  • Squamous cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Emerging drugs for squamous cell lung cancer. / Cheng, Haiying; Shcherba, Marina; Kandavelou, Karthikeya; Liang, Yuanxin; Liu, Huijie; Perez-Soler, Roman.

In: Expert Opinion on Emerging Drugs, Vol. 20, No. 1, 01.03.2015, p. 149-160.

Research output: Contribution to journalArticle

Cheng, Haiying ; Shcherba, Marina ; Kandavelou, Karthikeya ; Liang, Yuanxin ; Liu, Huijie ; Perez-Soler, Roman. / Emerging drugs for squamous cell lung cancer. In: Expert Opinion on Emerging Drugs. 2015 ; Vol. 20, No. 1. pp. 149-160.
@article{b20f336bca5f46d6af8af087c97282b5,
title = "Emerging drugs for squamous cell lung cancer",
abstract = "Introduction: The management of advanced NSCLC has been shifted by histology-driven treatment and molecularly targeted therapy, especially in lung adenocarcinoma. However, as the second most common histology in NSCLC, the treatment options for squamous cell lung cancer (SQCLC) remain very limited.Areas covered: The review first discusses the role of histology in management of NSCLC and new cytotoxic agents in SQCLC, and then addresses genomic characterization and potential molecular targets in SQCLC. The article then provides an overview for several major categories of novel molecularly targeted therapies and immune-based strategies with particular attention to ongoing SQCLC trials.Expert opinion: The key challenges in drug development are to uncover novel actionable targets and to identify predictive biomarkers. Progress in genomic analysis has identified some promising targetable genes and oncogenic pathways in SQCLC with a wave of targeted agents being tested in clinical trials. Immunotherapy has also raised great interest in management of SQCLC, especially agents targeting immune check points, cytotoxic T-lymphocyte antigen-4, programmed death-1 receptor and its ligands. Better understanding of tumor biology and development of novel targeted therapies will help to facilitate more effective personalized therapy for patients with this devastating illness.",
keywords = "Biomarker, New treatment, NSCLC, Squamous cell lung cancer, Targeted therapy",
author = "Haiying Cheng and Marina Shcherba and Karthikeya Kandavelou and Yuanxin Liang and Huijie Liu and Roman Perez-Soler",
year = "2015",
month = "3",
day = "1",
doi = "10.1517/14728214.2015.1001365",
language = "English (US)",
volume = "20",
pages = "149--160",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging drugs for squamous cell lung cancer

AU - Cheng, Haiying

AU - Shcherba, Marina

AU - Kandavelou, Karthikeya

AU - Liang, Yuanxin

AU - Liu, Huijie

AU - Perez-Soler, Roman

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Introduction: The management of advanced NSCLC has been shifted by histology-driven treatment and molecularly targeted therapy, especially in lung adenocarcinoma. However, as the second most common histology in NSCLC, the treatment options for squamous cell lung cancer (SQCLC) remain very limited.Areas covered: The review first discusses the role of histology in management of NSCLC and new cytotoxic agents in SQCLC, and then addresses genomic characterization and potential molecular targets in SQCLC. The article then provides an overview for several major categories of novel molecularly targeted therapies and immune-based strategies with particular attention to ongoing SQCLC trials.Expert opinion: The key challenges in drug development are to uncover novel actionable targets and to identify predictive biomarkers. Progress in genomic analysis has identified some promising targetable genes and oncogenic pathways in SQCLC with a wave of targeted agents being tested in clinical trials. Immunotherapy has also raised great interest in management of SQCLC, especially agents targeting immune check points, cytotoxic T-lymphocyte antigen-4, programmed death-1 receptor and its ligands. Better understanding of tumor biology and development of novel targeted therapies will help to facilitate more effective personalized therapy for patients with this devastating illness.

AB - Introduction: The management of advanced NSCLC has been shifted by histology-driven treatment and molecularly targeted therapy, especially in lung adenocarcinoma. However, as the second most common histology in NSCLC, the treatment options for squamous cell lung cancer (SQCLC) remain very limited.Areas covered: The review first discusses the role of histology in management of NSCLC and new cytotoxic agents in SQCLC, and then addresses genomic characterization and potential molecular targets in SQCLC. The article then provides an overview for several major categories of novel molecularly targeted therapies and immune-based strategies with particular attention to ongoing SQCLC trials.Expert opinion: The key challenges in drug development are to uncover novel actionable targets and to identify predictive biomarkers. Progress in genomic analysis has identified some promising targetable genes and oncogenic pathways in SQCLC with a wave of targeted agents being tested in clinical trials. Immunotherapy has also raised great interest in management of SQCLC, especially agents targeting immune check points, cytotoxic T-lymphocyte antigen-4, programmed death-1 receptor and its ligands. Better understanding of tumor biology and development of novel targeted therapies will help to facilitate more effective personalized therapy for patients with this devastating illness.

KW - Biomarker

KW - New treatment

KW - NSCLC

KW - Squamous cell lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84923297066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923297066&partnerID=8YFLogxK

U2 - 10.1517/14728214.2015.1001365

DO - 10.1517/14728214.2015.1001365

M3 - Article

C2 - 25557559

AN - SCOPUS:84923297066

VL - 20

SP - 149

EP - 160

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -